Ms Orla Gallagher

Clinical Medicine, School of Medicine and Population Health

Senior Technical Specialist - Histology

o.m.gallagher@sheffield.ac.uk
+44 114 215 9201

EU24, E Floor, The Medical School

Full contact details

Ms Orla Gallagher
Clinical Medicine, School of Medicine and Population Health
EU24, E Floor
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R & Khwaja A (2021) Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone, 143, 115699-115699.
Salam S, Gallagher O, Hughes D, Khwaja A & Eastell R (2020) The role of static bone histomorphometry in diagnosing renal osteodystrophy. Bone. View this article in WRRO
Salam S, Gallagher O, Gossiel F, Khwaja A & Eastell R (2020) The relationship between bone regulatory markers and bone turnover in renal osteodystrophy. Bone Reports, 13, 100670-100670.
Esapa CT, Piret SE, Nesbit MA, Thomas GP, Coulton LA, Gallagher OM, Simon MM, Kumar S, Mallon A-M, Bellantuono I , Brown MA et al (2018) An N‐Ethyl‐N‐Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion. JBMR Plus, 2(3), 154-163. View this article in WRRO
Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A & Eastell R (2018) Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.. Journal of the American Society of Nephrology, 29(5), 1557-1565. View this article in WRRO
Besio R, Maruelli S, Gioia R, Villa I, Grabowski P, Gallagher O, Bishop NJ, Foster S, De Lorenzi E, Colombo R , Diaz JLD et al (2015) Lack of prolidase causes a bone phenotype both in human and in mouse. Bone, 72, 53-64.

All publications

Journal articles

Salam S, Gallagher O, Gossiel F, Paggiosi M, Eastell R & Khwaja A (2021) Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone, 143, 115699-115699.
Salam S, Gallagher O, Hughes D, Khwaja A & Eastell R (2020) The role of static bone histomorphometry in diagnosing renal osteodystrophy. Bone. View this article in WRRO
Salam S, Gallagher O, Gossiel F, Khwaja A & Eastell R (2020) The relationship between bone regulatory markers and bone turnover in renal osteodystrophy. Bone Reports, 13, 100670-100670.
Salam S, Gallagher O, Gossiel F, Khwaja A & Eastell R (2020) P0885THE RELATIONSHIP BETWEEN BONE REGULATORY MARKERS AND BONE TURNOVER IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 35(Supplement_3).
Esapa CT, Piret SE, Nesbit MA, Thomas GP, Coulton LA, Gallagher OM, Simon MM, Kumar S, Mallon A-M, Bellantuono I , Brown MA et al (2018) An N‐Ethyl‐N‐Nitrosourea (ENU) Mutagenized Mouse Model for Autosomal Dominant Nonsyndromic Kyphoscoliosis Due to Vertebral Fusion. JBMR Plus, 2(3), 154-163. View this article in WRRO
Salam S, Gallagher O, Gossiel F, Paggiosi M, Khwaja A & Eastell R (2018) Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy.. Journal of the American Society of Nephrology, 29(5), 1557-1565. View this article in WRRO
Besio R, Maruelli S, Gioia R, Villa I, Grabowski P, Gallagher O, Bishop NJ, Foster S, De Lorenzi E, Colombo R , Diaz JLD et al (2015) Lack of prolidase causes a bone phenotype both in human and in mouse. Bone, 72, 53-64.
Foster S, Forestier-Zhang L, Grabowski P, Gallagher O, Madan S, Arundel P & Bishop N (2014) Direct fracture resistance testing of bone in children using the RPI instrument. Annals of Medicine and Surgery, 3(2), 49-50.
Hald A, Hansen RR, Thomsen MW, Ding M, Croucher PI, Gallagher O, Ebetino FH, Kassem M & Heegaard A-M (2009) Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.. Int J Cancer, 125(5), 1177-1185.
Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Vanderkerken K, Seehra JS & Croucher PI (2008) RAP-011, a soluble activin receptor type IIA IgG-Fc fusion protein, is a novel bone anabolic agent that prevents bone disease in multiple myeloma. CLIN EXP METASTAS, 25, 64-64.
Menu E, Jernberg-Wiklund H, De Raeve H, De Leenheer E, Coulton L, Gallagher O, Van Valckenborgh E, Larsson O, Axelson M, Nilsson K , Van Camp B et al (2007) Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.. Int J Cancer, 121(8), 1857-1861.
Rabin N, Kyriakou C, Coulton L, Gallagher OM, Buckle C, Benjamin R, Singh N, Glassford J, Otsuki T, Nathwani AC , Croucher PI et al (2007) A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer.. Leukemia, 21(10), 2181-2191.
Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher PI (2007) An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.. Cancer Res, 67(1), 202-208.
Rabin N, Kyriakou C, Benjamin R, Pizzey A, Gallagher O, Singh N, Buckle C, Croucher P, Nathwani A & Yong K (2006) Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.. Blood, 108(11), 505-505.

Conference proceedings papers

Salam S, Gallagher O, Hughes D, Khwaja A & Eastell R (2021) Trabecular bone structure in advanced chronic kidney disease: Comparison of bone biopsy assessment using microCT and histomorphometry. Bone Reports, Vol. 14(Supplement). Digital Congress, 6 May 2021 - 8 May 2021. View this article in WRRO
Salam S, Paggiosi M, Gallagher O, Eastell R & Khwaja A (2019) FP610 Vascular calcification in advanced CKD and its relationship with bone microstructures. Nephrology Dialysis Transplantation, Vol. 34(Supplement_1). Budapest, Hungary, 13 June 2019 - 16 June 2019. View this article in WRRO
Salam S, Paggiosi M, Gallagher O, Eastell R & Khwaja A (2019) VASCULAR CALCIFICATION IN ADVANCED CKD AND ITS RELATIONSHIP WITH BONE MICROSTRUCTURES. NEPHROLOGY DIALYSIS TRANSPLANTATION, Vol. 34
Foster S, Grabowski PS, Gallagher O, Besio R, Rossi A, Bishop N & Forlino A (2013) Prolidase deficient mice are osteoporotic in early life. Bone Abstracts, Vol. 2 (pp OC22-OC22)
Forestier-Zhang L, Grabowski PS, Gallagher O, Patel A, Madan S, Arundel P & Bishop N (2013) Assessing bone quality and fracture resistance in children using microindentation. Bone Abstracts, Vol. 2 (pp P86-P86)
Chantry AD, Baud'huin M, Coulton L, Gallagher O, Evans H, Lath D, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher PI (2011) Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the development of osteolytic bone disease in the 5T2MM murine model of myeloma. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 153 (pp 7-7)
Williams A, Lawson M, Bos T, Amani E, Hough J, Evans H, Lath D, Gallagher O, Coulton L, Vanderkerken K & Croucher P (2010) Imaging and quantitation of multiple myeloma in calvariae. BONE, Vol. 47 (pp S328-S328)
Chantry A, Coulton L, Gallagher O, Evans H, Seehra J, Pearsall S, De Raeve H, Vanderkerken K & Croucher R (2009) Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma. BONE, Vol. 44 (pp S55-S55)
Chantry AD, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 22(7) (pp 1118-1118)
Rabin N, Coulton L, Gallagher OM, Benjamin R, Singh N, McIntosh JH, Buckle C, Nathwani A, Croucher P & Yong K (2007) Micro-computer tomography (MICROCT) analysis demonstrates extensive bone loss in the KMS-12-BM xenogeneic murine model of myeloma. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 136-136)
Chantry A, Heath D, Coulton L, Gallagher O, Evans H, Seehra J, Vanderkerken K & Croucher PI (2007) A soluble activin type II receptor prevents myeloma bone disease. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, Vol. 92(6) (pp 133-133)
Rabin N, Kyriakou C, Benjamin R, Pizzey A, Gallagher O, Singh N, Buckle C, Croucher P, Nathwani A & Yong K (2006) Gene modified human mesenchymal stem cells expressing osteoprotegerin inhibit osteoclast activation and increase trabecular bone area in a xenogeneic murine model of myeloma.. BLOOD, Vol. 108(11) (pp 153A-153A)
Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher P (2006) An osteoprotegerin-like peptidomimetic (OP3-4) inhibits osteoclastic bone resorption and osteolytic bone disease in multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S82-S82)
Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces turnour burden in a syngeneic model of multiple myeloma.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21 (pp S137-S137)
Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher PI (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1160-1160)
Heath DJ, Vanderkerken K, Cheng X, Gallagher O, Prideaux M, Murali R & Croucher PI (2006) An osteoprotegerin-like peptidomimetic (OP3-4) inhibits osteoclastic bone resorption and osteolytic bone disease in multiple myeloma. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 21(7) (pp 1151-1151)
Lawson MA, Coulton L, Ebetino FH, Gallagher O, Prideaux M, Vanderkerken K & Croucher P (2006) Risedronate prevents bone disease and reduces tumour burden in a syngeneic model of multiple myeloma. CANCER TREATMENT REVIEWS, Vol. 32 (pp S35-S35)
Kartsogiannis V, Ly C, Zhou H, Gallagher O, Buckle C, De Leenheer E, Vanderkerken K, Ng KN, Martin TJ, Gillespie MT & Croucher PI (2005) Expression of RANKL, OPG, PTHrP and OCIL in multiple myeloma are influenced by the tumor cells' proximity to bone.. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 20(9) (pp S211-S211)
Kartsogiannis V, Ly C, Zhou H, Gallagher O, De Leenhey E, Buckle C, Ng KW, Martin TJ, Gillespie MT & Croucher P (2005) Expression of PTHrP, RANK, OPG and OCIL in multiple myeloma are influenced by the tumor cells' proximity to bone. CANCER TREATMENT REVIEWS, Vol. 31 (pp S25-S25)
Roberts SA, Gallagher O, Jones RD, English KM, Jones TH & Channer KS (2002) Quantification of lumen occlusion due to neointimal cell growth in cultured thoracic aortae from testicular feminized and control mice. BRITISH JOURNAL OF PHARMACOLOGY, Vol. 137
Forestier-Zhang LY, Patel A, Gallagher OM, Grabowski P, Madan S, Arundel P & Bishop NJ () Direct fracture resistance testing of bone in infants and children. Medical School Research Day. University of Sheffield, 11 June 2012 - 12 June 2012.